Link to this page
Prostate Cancer Ontology
Acronym | PCAO |
Visibility | Public |
Description | Here, we introduce the Prostate cancer ontology (PCaO) as a comprehensive semantic framework covering the whole breadth of the PCa’s knowledge domain. This ontology with a subclass-based taxonomic hierarchy not only covers the broad spectrum of major biomedical concepts from molecular to clinical features of the disease, but also the different views on disease features held by molecular biologists, clinicians and drug developers. PCaO organized under three biological viewpoints, i.e., epidemiology, diagnosis, and treatment. Note: The prostate cancer ontology version 1.0 (PCAO 1.0) was published by Hua Min in 2009 (PMID: 19497389). |
Status | Beta |
Format | OWL |
Contact | Chunjiang Yu, 743434289@qq.com Bairong Shen, bairong.shen@scu.edu.cn Qiang Wei , weiqiang933@126.com |
Categories | Health, Human |
No views of PCAO available
Id | http://www.semanticweb.org/ontologies/2018/1/ProstateCancer.owl#Docetaxel_regimen
http://www.semanticweb.org/ontologies/2018/1/ProstateCancer.owl#Docetaxel_regimen
|
---|---|
Preferred Name | Docetaxel regimen |
Definitions |
A significant improvement in median survival of 2-2.5 months occurred with docetaxel-based chemotherapy|compared to mitoxantrone + prednisone therapy. The standard for first-line cytotoxic chemotherapy|is docetaxel using the same regimen as in the TAX 327 trial, that is, 75 mg/m2 3 weekly combined with|prednisone 5 mg BID, up to 10 cycles, and palliation is the main target.|The patients considered for docetaxel represent a heterogeneous population. Several poor|prognostic factors have been described, such as a PSA level > 114 ng/mL, PSA-DT < 55 days, or the presence|of visceral metastases. A better risk group definition has recently been presented, based on the TAX|327 study cohort. The predictive factors were visceral metastases, pain, anaemia (Hb < 13 g/dL), bone scan|progression, and prior estramustine before docetaxel. Patients were categorised into three risk groups: low risk|(0 or 1 factor), intermediate (2 factors) and high risk (3 or 4 factors), leading to three different lengths of median|OS: 25.7, 18.7 and 12.8 months, respectively. In addition, two independent studies have suggested that|improved survival can be predicted by C-reactive protein (CRP) levels < 8 mg/L (HR, 2.96). Age by|itself is not a contraindication to docetaxel.
|
Type | http://www.w3.org/2002/07/owl#Class |
All Properties
definition | A significant improvement in median survival of 2-2.5 months occurred with docetaxel-based chemotherapy|compared to mitoxantrone + prednisone therapy. The standard for first-line cytotoxic chemotherapy|is docetaxel using the same regimen as in the TAX 327 trial, that is, 75 mg/m2 3 weekly combined with|prednisone 5 mg BID, up to 10 cycles, and palliation is the main target.|The patients considered for docetaxel represent a heterogeneous population. Several poor|prognostic factors have been described, such as a PSA level > 114 ng/mL, PSA-DT < 55 days, or the presence|of visceral metastases. A better risk group definition has recently been presented, based on the TAX|327 study cohort. The predictive factors were visceral metastases, pain, anaemia (Hb < 13 g/dL), bone scan|progression, and prior estramustine before docetaxel. Patients were categorised into three risk groups: low risk|(0 or 1 factor), intermediate (2 factors) and high risk (3 or 4 factors), leading to three different lengths of median|OS: 25.7, 18.7 and 12.8 months, respectively. In addition, two independent studies have suggested that|improved survival can be predicted by C-reactive protein (CRP) levels < 8 mg/L (HR, 2.96). Age by|itself is not a contraindication to docetaxel. |
---|---|
label | Docetaxel regimen
|
prefLabel | Docetaxel regimen
|
prefixIRI | ProstateCancer:Docetaxel_regimen
|
subClassOf | |
type | |
ChineseLabel | 多西他赛方案
|
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |
- Problem retrieving properties:
Notes
Add NCBO Web Widgets to your site for PCAO
Widget type | Widget demonstration |
---|---|
|
Step 2: Follow the Instructions
For more help visit NCBO Widget Wiki |
|
Example 1 (start typing the class name to get its full URI)
Example 2 (get the ID for a class) Example 3 (get the preferred name for a class) Step 2: Follow the Instructions
For more help visit NCBO Widget Wiki |
|
Step 2: Follow the InstructionsCopy the code below and paste it to your HTML page <iframe frameborder="0" src="/widgets/visualization?ontology=PCAO&class=http%3A%2F%2Fwww.semanticweb.org%2Fontologies%2F2018%2F1%2FProstateCancer.owl%23Estramustine&apikey=YOUR_API_KEY"></iframe> For more help visit NCBO Widget Wiki |
|
Step 2: Follow the InstructionsCopy the code below and paste it to your HTML page <link rel="stylesheet" type="text/css" href="/widgets/jquery.ncbo.tree.css"> <script src="/widgets/jquery.ncbo.tree-2.0.2.js"></script> <div id="widget_tree"></div> var widget_tree = $("#widget_tree").NCBOTree({ apikey: "YOUR_API_KEY", ontology: "PCAO" }); You can also view a detailed demonstration For more help visit NCBO Widget Wiki |